🇺🇸 FDA
Patent

US 10400045

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

granted A61KA61K47/6811A61K47/6829

Quick answer

US patent 10400045 (Internalizing human monoclonal antibodies targeting prostate and other cancer cells) held by The Regents of the University of California expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K47/6811, A61K47/6829, A61K47/6849, A61K47/6869